Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Manometry | 1 | 2013 | 45 | 0.410 |
Why?
|
| Esophageal Achalasia | 1 | 2013 | 61 | 0.380 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 187 | 0.300 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 426 | 0.280 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 790 | 0.240 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2023 | 8 | 0.200 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2023 | 24 | 0.190 |
Why?
|
| Ethanol | 2 | 2023 | 273 | 0.180 |
Why?
|
| Oxadiazoles | 1 | 2021 | 40 | 0.170 |
Why?
|
| Colonic Polyps | 1 | 2022 | 137 | 0.170 |
Why?
|
| Indans | 1 | 2021 | 37 | 0.170 |
Why?
|
| Arteriosclerosis | 2 | 2002 | 112 | 0.170 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 425 | 0.170 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2021 | 67 | 0.170 |
Why?
|
| Intensive Care Units | 2 | 2021 | 460 | 0.160 |
Why?
|
| Pneumonia | 1 | 2022 | 196 | 0.160 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 67 | 0.160 |
Why?
|
| Central Nervous System Depressants | 1 | 2000 | 45 | 0.160 |
Why?
|
| Lipoproteins | 1 | 2000 | 138 | 0.160 |
Why?
|
| Rheumatologists | 1 | 2019 | 7 | 0.150 |
Why?
|
| Insurance, Disability | 1 | 2019 | 2 | 0.150 |
Why?
|
| Aortic Diseases | 1 | 2000 | 104 | 0.150 |
Why?
|
| Sick Leave | 1 | 2019 | 15 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2022 | 381 | 0.150 |
Why?
|
| Occupational Health | 1 | 2019 | 40 | 0.150 |
Why?
|
| Cholesterol | 1 | 2000 | 367 | 0.140 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2019 | 187 | 0.130 |
Why?
|
| Microbiota | 1 | 2023 | 425 | 0.130 |
Why?
|
| Oxygen | 1 | 2021 | 781 | 0.120 |
Why?
|
| Hospitalization | 1 | 2021 | 946 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 800 | 0.110 |
Why?
|
| Models, Biological | 1 | 2021 | 1810 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 1069 | 0.100 |
Why?
|
| Liver | 3 | 2023 | 1231 | 0.100 |
Why?
|
| Electric Impedance | 1 | 2013 | 117 | 0.100 |
Why?
|
| Aged | 6 | 2022 | 20927 | 0.090 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2011 | 26 | 0.090 |
Why?
|
| Nutritional Status | 1 | 2011 | 82 | 0.080 |
Why?
|
| Gastrectomy | 1 | 2011 | 70 | 0.080 |
Why?
|
| Duodenum | 1 | 2011 | 112 | 0.080 |
Why?
|
| Stomach | 1 | 2011 | 116 | 0.080 |
Why?
|
| Humans | 12 | 2023 | 95992 | 0.070 |
Why?
|
| Male | 7 | 2022 | 45792 | 0.070 |
Why?
|
| Female | 7 | 2022 | 49980 | 0.050 |
Why?
|
| Middle Aged | 5 | 2022 | 28299 | 0.050 |
Why?
|
| Macrophage-1 Antigen | 1 | 2002 | 18 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 73 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 75 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 79 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 81 | 0.040 |
Why?
|
| Serbia | 1 | 2021 | 3 | 0.040 |
Why?
|
| Bradycardia | 1 | 2021 | 47 | 0.040 |
Why?
|
| Serum Albumin, Human | 1 | 2021 | 5 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 190 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 32 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 164 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 91 | 0.040 |
Why?
|
| Adult | 4 | 2021 | 28636 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2022 | 10307 | 0.040 |
Why?
|
| Monocytes | 1 | 2002 | 219 | 0.040 |
Why?
|
| Diet, Atherogenic | 1 | 2000 | 14 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2021 | 151 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2022 | 304 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 276 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7224 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2000 | 91 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 246 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 299 | 0.040 |
Why?
|
| Work Capacity Evaluation | 1 | 2019 | 5 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 281 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 351 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 346 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 1561 | 0.030 |
Why?
|
| Aging | 1 | 2022 | 766 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 448 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1792 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 835 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1063 | 0.030 |
Why?
|
| Hypertension | 1 | 2021 | 775 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1982 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2498 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2000 | 3483 | 0.020 |
Why?
|
| Risk Factors | 1 | 2022 | 5992 | 0.020 |
Why?
|
| Digestion | 1 | 2011 | 8 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 127 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 318 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 460 | 0.020 |
Why?
|
| Mice | 2 | 2002 | 12525 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 310 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 9228 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 7034 | 0.020 |
Why?
|
| Animals | 2 | 2002 | 28901 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3922 | 0.010 |
Why?
|
| Quality of Life | 1 | 2011 | 1816 | 0.010 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2002 | 16 | 0.010 |
Why?
|
| Integrins | 1 | 2002 | 79 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2002 | 136 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2002 | 430 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 750 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1560 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 1827 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2002 | 2160 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2534 | 0.010 |
Why?
|